Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
By J. Douillard, K. Oliner, S. Siena, J. Tabernero, R. Burkes, M. Barugel, Y. Humblet, G. Bodoky, D. Cunningham, J. Jassem and 12 more. New England Journal of Medicine, 2013
2,174 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/fb1f99228db018a98b98f5715d11a94831869d6e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017, background): “Independent from tumour localization, RAS mutant tumour status is known to be a very strong negative predictor for EGFR antibody therapy whilst, RAS wt tumour status is a relatively strong predictive marker for the efficacy of EGFR antibody therapy [43, 45, 46, 58].”
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “Furthermore, recent evidence from the PRIME study with panitumumab [48], from the CRYSTAL study with cetuximab [49] and from other studies of EGFR monoclonal antibody therapies has shown that mutations other than those in KRAS exon 2 [i.”
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “Panitumumab also increases objective RR (ORR), PFS and OS when combined with FOLFOX in the first-line treatment of RAS WT mCRC [24, 25].”
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, background): “99) 4 [62]”
- The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges (2019, background): “The National Comprehensive Cancer Network (NCCN) guidelines for colorectal cancer recommend that patients should screen for KRAS/ NRAS/BRAF mutations, because these mutations are indicative of poor response to cetuximab and panitumumab [159-162].”
- Controversies in colorectal cancer: First line treatment with epidermal growth factor inhibitors and RAS in 2014 (2014, methodology): “In the PRIME study,[6] of 1183 patients who entered, 512 had wild type KRAS exon 2 and were randomized to receive treatment with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) with or without panitumumab.”
- Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. (2015, background): “This frequency is similar to those reported in other first-line mCRC studies, which used pyrosequencing or dideoxy sequencing/WAVE analysis.(7,18,19) In common with these studies and also the parallel RAS analysis of the OPUS study,(13) the most common location of RAS mutations outside of KRAS exon ”